Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited reported a slight increase in revenue for the first half of 2025, driven by its innovative and barrier products, which now account for over half of its total revenue. Despite facing challenges from price reductions due to centralized procurement, the company showed resilience through strategic execution and risk management. However, the profit attributable to the company’s owners decreased by 25% compared to the previous year, primarily due to reduced gains from Telix investment and increased marketing expenses. The company continues to invest heavily in research and development to support its growth strategy.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on innovative and barrier-breaking products. The company is committed to innovation-driven development and product portfolio optimization, with a strong emphasis on global expansion and sustainable growth.
Average Trading Volume: 28,204,430
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.78B
For an in-depth examination of 0512 stock, go to TipRanks’ Overview page.